
West Pharmaceutical Services (WST) closed at $223.77, with analysts projecting a mean price target of $284, representing a potential 26.9% upside; however, the article cautions against relying solely on price targets due to potential biases. Despite skepticism surrounding price targets, analysts' upward revisions to EPS estimates and a Zacks Rank #2 (Buy) suggest a positive outlook for WST, indicating a possible upside in the near term.
West Pharmaceutical Services (WST), which recently closed at $223.77, has garnered analyst attention with a mean price target of $284, implying a potential 26.9% upside from its current level, despite a modest 2% gain over the past four weeks. This average is based on 10 short-term targets spanning $245 to $355, with a standard deviation of $34.94. However, the article prudently cautions against over-reliance on such price targets, citing research on their potential unreliability and inherent analyst biases. More significantly for WST, a strong consensus among analysts regarding an upward trajectory in earnings estimate revisions provides a more robust foundation for potential stock appreciation. Specifically, the Zacks Consensus Estimate for the current fiscal year has increased by 0.2% over the last 30 days, supported by one upward revision and no negative revisions. Complementing this, WST carries a Zacks Rank #2 (Buy), positioning it within the top 20% of over 4,000 stocks ranked by Zacks, a system noted for its externally-audited track record and considered a more conclusive indicator of near-term upside potential based on earnings estimate strength and revisions.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment